Spartalizumab
As of the edition of 20 October 2026, Spartalizumab is an antibody: in active development; acts on PDCD1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2030
- Kind
- Antibody
- Registered trials
- 61, 24 stopped early
- Disease areas
- Cancer; Skin and connective tissue; Lungs and airways; Digestive system; Pregnancy and women's health; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| PDCD1 | Programmed cell death protein 1 | Q15116 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 34 | 13 | 3 | 17 |
| Phase 2 | 26 | 13 | 3 | 6 |
| Phase 3 | 1 | 0 | 0 | 1 |
| All trials | 61 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Novartis | Lead sponsor of trials | 2011 to now |
| Palobiofarma | Lead sponsor of trials | 2015 to now |